CN104491310B - Anti-fatigue composition and its preparation method and application - Google Patents
Anti-fatigue composition and its preparation method and application Download PDFInfo
- Publication number
- CN104491310B CN104491310B CN201410789238.7A CN201410789238A CN104491310B CN 104491310 B CN104491310 B CN 104491310B CN 201410789238 A CN201410789238 A CN 201410789238A CN 104491310 B CN104491310 B CN 104491310B
- Authority
- CN
- China
- Prior art keywords
- parts
- fatigue
- composition
- preparation
- nourish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 27
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 16
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 16
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 15
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 235000000661 Rosa laevigata Nutrition 0.000 claims abstract description 5
- 241001278833 Rosa laevigata Species 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- -1 flavouring Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000009702 powder compression Methods 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 49
- 210000003734 kidney Anatomy 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 26
- 210000004185 liver Anatomy 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 17
- 210000000952 spleen Anatomy 0.000 abstract description 16
- 210000004072 lung Anatomy 0.000 abstract description 15
- 235000004879 dioscorea Nutrition 0.000 abstract description 11
- 241000735234 Ligustrum Species 0.000 abstract description 7
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 235000004789 Rosa xanthina Nutrition 0.000 abstract description 3
- 241000220222 Rosaceae Species 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 24
- 239000006191 orally-disintegrating tablet Substances 0.000 description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 230000009182 swimming Effects 0.000 description 18
- 239000000686 essence Substances 0.000 description 17
- 206010016256 fatigue Diseases 0.000 description 17
- 229920002527 Glycogen Polymers 0.000 description 13
- 229940096919 glycogen Drugs 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 244000281702 Dioscorea villosa Species 0.000 description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000167854 Bourreria succulenta Species 0.000 description 7
- 235000019693 cherries Nutrition 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940109275 cyclamate Drugs 0.000 description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241001632410 Eleutherococcus senticosus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 206010059013 Nocturnal emission Diseases 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 240000008254 Rosa chinensis Species 0.000 description 2
- 235000000664 Rosa chinensis Nutrition 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229930190029 eleutheroside Natural products 0.000 description 2
- 239000008769 eleutheroside Substances 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910002055 micronized silica Inorganic materials 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000221775 Hypocreales Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003219 hemolytic agent Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗疲劳组合物及其制备方法和应用,属于医药技术领域。该组合物的有效成分由以下重量份的原料制备而成:刺五加10.0‑20.0份,蛹虫草8.0‑18.0份,山药5.0‑23.0份,金樱子3.0‑10.0份,女贞子3.0‑10.0份。该抗疲劳组合物将刺五加,蛹虫草,山药,金樱子,女贞子相配合,以蛹虫草益肾补肺,补精髓,主补先天之气,为君药;以刺五加益气健脾,补肾安神,主补后天之气,为臣药;以山药益气养阴,女贞子补益肝肾,共为佐药;以金樱子固精涩肠,调和药性为使药。这几种原料相互配合,协同作用,共同起效,起到抗疲劳的功效。The invention discloses an anti-fatigue composition and its preparation method and application, belonging to the technical field of medicine. The active ingredients of the composition are prepared from the following raw materials in parts by weight: 10.0-20.0 parts of Acanthopanax, 8.0-18.0 parts of Cordyceps militaris, 5.0-23.0 parts of Chinese yam, 3.0-10.0 parts of Rosa laevigata, 3.0-10.0 parts of Ligustrum lucidum 10.0 servings. The anti-fatigue composition combines Acanthopanax militaris, Cordyceps militaris, Chinese yam, Rosaceae, and Ligustrum lucidum, uses Cordyceps militaris to nourish the kidneys, nourish the lungs, nourish the essence, and mainly nourish the innate qi, and is the king drug; Invigorate qi and invigorate the spleen, invigorate the kidney and calm the nerves, mainly nourish the acquired qi, and serve as ministerial medicine; use yam to nourish qi and nourish yin, and privet fruit to nourish the liver and kidney, which are used as adjuvant medicine; medicine. These several kinds of raw materials cooperate with each other, act synergistically, work together, and play the effect of anti-fatigue.
Description
技术领域technical field
本发明涉及医药技术领域,特别是涉及一种抗疲劳组合物及其制备方法和应用。The invention relates to the technical field of medicine, in particular to an anti-fatigue composition and its preparation method and application.
背景技术Background technique
随着社会生活节奏的加快,现代人长期处于工作紧张、竞争压力大的环境下,导致情绪不稳定,极容易产生疲劳,陷入亚健康状态。With the acceleration of the pace of social life, modern people have long been in an environment of intense work and high competitive pressure, which leads to emotional instability, fatigue, and a sub-healthy state.
疲劳分为生理性疲劳和病理性疲劳两种。其中:生理性疲劳可以通过正常的休息得到缓解,而病理性疲劳则无法通过休息得到有效缓解,严重地影响日常的生活和工作,是人类健康的极大隐患,必须借助药物或心理疗法等方法给予治疗。Fatigue is divided into two types: physiological fatigue and pathological fatigue. Among them: Physiological fatigue can be relieved by normal rest, but pathological fatigue cannot be effectively relieved by rest, which seriously affects daily life and work, and is a great hidden danger to human health. Drugs or psychotherapy must be used. Give treatment.
疲劳若是长时间得不到缓解,就会发展为慢性疲劳综合症,严重的甚至导致猝死,其典型猝死症状即为“过劳死”。流行病学调查显示:疲劳多发于中高等教育程度的中年人群,尤以女性居多,且有朝着青年人群发展蔓延的趋势,已经成为21世纪威胁人类健康的主要隐患之一。If fatigue is not relieved for a long time, it will develop into chronic fatigue syndrome, which can even lead to sudden death in severe cases. The typical sudden death symptom is "death from overwork". Epidemiological surveys show that fatigue is more common in middle-aged people with higher education, especially in women, and it tends to spread to young people. It has become one of the major hidden dangers that threaten human health in the 21st century.
目前,临床上用于抗疲劳的药物大多属中枢神经兴奋剂的化学药,具有成瘾性和依赖性,极大的限制了其临床应用。因此,开发具有抗疲劳功效且无毒副作用的纯天然保健食品具有极为重要的现实意义和社会意义。At present, most of the drugs used clinically for anti-fatigue are chemical drugs of central nervous system stimulants, which are addictive and dependent, which greatly limits their clinical application. Therefore, the development of pure natural health food with anti-fatigue effect and no side effects has extremely important practical and social significance.
发明内容Contents of the invention
基于此,本发明的目的在于克服现有技术的缺陷,提供一种抗疲劳组合物,该组合物具有很好的抗疲劳作用,且全由天然成分组成,具有无成瘾性和依赖性,副作用小的优点。Based on this, the purpose of the present invention is to overcome the defects of the prior art, to provide an anti-fatigue composition, which has a good anti-fatigue effect, and is completely composed of natural ingredients, without addiction and dependence, Advantages of less side effects.
为实现上述目的,本发明采取以下技术方案:To achieve the above object, the present invention takes the following technical solutions:
一种抗疲劳组合物,所述组合物的有效成分由以下重量份的原料制备而成:An anti-fatigue composition, the active ingredient of which is prepared from the following raw materials in parts by weight:
刺五加10.0-20.0份,蛹虫草8.0-18.0份,山药5.0-23.0份,金樱子3.0-10.0份,女贞子3.0-10.0份。10.0-20.0 parts of Acanthopanax, 8.0-18.0 parts of Cordyceps militaris, 5.0-23.0 parts of Chinese yam, 3.0-10.0 parts of golden cherry, 3.0-10.0 parts of Ligustrum lucidum.
本发明的抗疲劳组合物,以中医药理论为指导,认为疲劳现象的出现,与五脏的失调有密切的关系,如四肢无力多与脾胃有关,腰酸腿软多与肾脏有关,气力不足多与肺脏有关,头脑不清多与心脏有关,不耐疲劳多与肝脏有关。人的整个生命活动,全赖于“元气”,元气禀赋于先天(肾)而滋养于后天(脾胃),是人体能量的源泉,元气与不同脏器的结合产生不同的功用,因此,元气虚弱会导致人的各个功能处于低迷抑制状态,这也是疲劳产生的根本原因。因此,对于疲劳的治疗不仅要补益五脏,更不能忽视对“气”的补充。The anti-fatigue composition of the present invention is guided by the theory of traditional Chinese medicine. It is believed that the appearance of fatigue is closely related to the imbalance of the five internal organs. For example, the weakness of the limbs is mostly related to the spleen and stomach, the soreness of the waist and legs is mostly related to the kidneys, and the lack of strength is mostly related to the kidneys. It is related to the lungs, confusion is mostly related to the heart, and fatigue is mostly related to the liver. The whole life activities of a person depend entirely on "vital energy". Vitality is endowed innate (kidney) and nourished in acquired (spleen and stomach). It is the source of energy for the human body. The combination of vitality and different organs produces different functions. It will cause people's various functions to be in a depressed and inhibited state, which is also the root cause of fatigue. Therefore, the treatment of fatigue should not only benefit the five internal organs, but also cannot ignore the supplement of "Qi".
在上述研究基础上,本发明中将刺五加,蛹虫草,山药,金樱子,女贞子相配合,以益肾补肺,健脾益气为治法,按照君臣佐使的组方原则进行药物配伍。方中蛹虫草益肾补肺,补精髓,主补先天之气为君药;刺五加益气健脾,补肾安神,主补后天之气为臣药;山药益气养阴,女贞子补益肝肾为佐药;金樱子固精涩肠,调和药性为使药。这几种原料相互配合,协同作用,共同起效,起到抗疲劳的功效。On the basis of the above research, in the present invention, Acanthopanax, Cordyceps militaris, Chinese yam, Fructus Rosa, and Fructus Ligustrum are matched, and the method of treating the disease is to nourish the kidney and nourish the lung, invigorate the spleen and replenish qi, and carry out according to the prescription principle of the monarch, minister and assistant envoy. Drug Compatibility. In the prescription, Cordyceps militaris nourishes the kidneys and lungs, nourishes the essence, and is the king drug for nourishing the innate qi; Acanthopanax senticosus nourishes the spleen, nourishes the kidney and calms the nerves, and is the subject medicine for nourishing the acquired qi; Invigorating the liver and kidney is an adjuvant drug; Fructus Rosa japonica solidifies essence and astringent intestines, and reconciles the properties of the medicine as an adjuvant drug. These several kinds of raw materials cooperate with each other, act synergistically, work together, and play the effect of anti-fatigue.
方中:蛹虫草(属于肉座菌目,麦角菌科,虫草属,又名北冬虫夏草),味甘,性平,归肾、肺经。具有益肾补肺,补精髓,止血化痰的功效。用于阳痿遗精,久咳虚喘,劳嗽痰血。蛹虫草的主要成分包括核苷类、多糖、糖醇和甾醇类物质。现代药理学研究表明,蛹虫草能够促进细胞免疫而抑制体液免疫,并促进骨髓造血干细胞(CFU-3)、红系祖细胞(CFU-E BFU-E)以及骨髓成纤维祖细胞(CFU-E)的增殖,同时还有雄性激素样作用。本方以蛹虫草为君药,旨在发挥其益肾补肺,补精髓的作用,滋肾精以补先天之本,益肺气以达宣降之功。Prescription: Cordyceps militaris (belonging to Hypocreales, Ergotaceae, Cordyceps genus, also known as Cordyceps militaris), sweet in taste, neutral in nature, and belongs to kidney and lung meridians. It has the effects of nourishing the kidney and nourishing the lung, nourishing the essence, stopping bleeding and resolving phlegm. For impotence and nocturnal emission, chronic cough with dyspnea due to deficiency, labor cough with phlegm and blood. The main components of Cordyceps militaris include nucleosides, polysaccharides, sugar alcohols and sterols. Modern pharmacological studies have shown that Cordyceps militaris can promote cellular immunity and inhibit humoral immunity, and promote bone marrow hematopoietic stem cells (CFU-3), erythroid progenitor cells (CFU-E BFU-E) and bone marrow fibroblast progenitor cells (CFU-E ) proliferation, as well as androgen-like effects. This prescription uses Cordyceps militaris as the monarch drug, aiming to exert its function of nourishing the kidney, nourishing the lung and nourishing the essence, nourishing the essence of the kidney to nourish the innate essence, and nourishing the lung qi to achieve the function of descending.
刺五加(属于伞形目,五加科,五加属),味辛、微苦,性温,归脾、肾、心经。具有益气健脾,补肾安神之功效。用于脾肾阳虚,体虚乏力,食欲不振,腰膝酸痛,失眠多梦。现代医学研究表明,刺五加的主要成分——刺五加苷,与人参有着相似的功效,能够刺激精神和身体活力,增加持久力、敏捷性和学习能力,延长大鼠负荷游泳时间,且小鼠爬绳试验和活动能量的结果均证明了刺五加甙的抗疲劳作用。本方以刺五加为臣药,发挥其益气健脾的滋补后天之气作用的同时,运用补肾安神的作用改善患者运动后机体恢复功能。Acanthopanax (belonging to Umbelliferae, Araliaceae, Aralis genus), pungent in taste, slightly bitter, warm in nature, belongs to the spleen, kidney, and heart channels. It has the effects of nourishing qi, invigorating the spleen, invigorating the kidney and calming the nerves. For spleen and kidney yang deficiency, physical weakness and fatigue, loss of appetite, soreness of the waist and knees, insomnia and dreaminess. Modern medical research shows that eleutheroside, the main component of eleuthero, has similar effects to ginseng, can stimulate mental and physical vitality, increase endurance, agility and learning ability, prolong the load swimming time of rats, and The results of the mouse climbing rope test and activity energy all proved the anti-fatigue effect of eleutheroside. This prescription uses Acanthopanax acanthopanax as the ministerial drug, while exerting its effect of nourishing Qi and invigorating the spleen and nourishing acquired qi, at the same time, it uses the effect of nourishing the kidney and calming the nerves to improve the recovery function of the patient's body after exercise.
山药(为薯蓣科植物薯蓣Dioscorea opposita Thunb.的干燥根茎),味甘,性平,归脾、肺、肾经。具有益气养阴,补益脾肺,补肾固精之功效。用于脾虚食少,大便溏泄,肺虚咳喘,遗精尿频,阴虚消渴。现代药学研究表明,山药含有多种黏蛋白、淀粉酶、皂苷、多糖及膳食纤维,具有降血脂,助消化,增强免疫功能的作用。Chinese yam (the dry rhizome of Dioscorea opposita Thunb.), sweet in taste and flat in nature, returns to the spleen, lung and kidney channels. It has the effects of nourishing qi and nourishing yin, nourishing spleen and lung, nourishing kidney and strengthening essence. For insufficiency of the spleen, lack of food, loose stool, cough and asthma due to lung deficiency, nocturnal emission, frequent urination, deficiency of yin and quenching thirst. Modern pharmaceutical research shows that yam contains a variety of mucins, amylases, saponins, polysaccharides and dietary fiber, which can lower blood fat, help digestion, and enhance immune function.
女贞子(为木犀科植物女贞Ligustrum lucidum Ait.的干燥成熟果实),味甘、苦,性凉。归肝、肾经。具有补益肝肾,明目,清虚热的功效。用于头晕目眩,须发早白,视物昏花,阴虚发热。女贞子的主要的成分为萜类、苷、有机酸和多糖类等物质,其中齐墩果酸和女贞子多糖是女贞子调节机体免疫功能的主要成分。Ligustrum lucidum (the dried ripe fruit of Ligustrum lucidum Ait.), sweet in the mouth, bitter in the mouth, cool in nature. Return liver, kidney channel. It has the effects of nourishing liver and kidney, improving eyesight and clearing deficiency and heat. Used for dizziness, premature graying of beard and hair, dim vision, yin deficiency and fever. The main components of Ligustrum lucidum are terpenoids, glycosides, organic acids and polysaccharides, among which oleanolic acid and Ligustrum lucidum polysaccharides are the main components of Ligustrum lucidum regulating the body's immune function.
本发明中以山药和女贞子为佐药,旨在辅助君臣诸药补气作用的同时佐以山药的养阴固精和女贞子的补肝清热,达到气阴双补、固精平肝的目的。In the present invention, yam and Ligustrum lucidum are used as adjuvant medicines, aiming at assisting the qi-tonifying effect of various medicines for monarchs and ministers, and at the same time assisting with nourishing yin and strengthening essence of yam and nourishing liver and clearing away heat of Ligustrum lucidum, so as to achieve both nourishment of qi and yin, and flattening of essence. purpose of the liver.
金樱子(属于蔷薇目,蔷薇科,蔷薇属),味甘、微酸、涩,性平,归肾、膀胱、大肠经。具有固精涩肠,缩尿止泻的功效。用于滑精,遗尿,小便频数,脾虚泻痢,肺虚喘咳,自汗盗汗,崩漏带下。方中以金樱子为使药,在发挥其固精涩肠作用的同时,利用其药性平和的特点调和以上诸药的药性。Fructus Rosa Rosa (belonging to Rosaceae, Rosaceae, Rosa), sweet in the mouth, slightly sour, astringent, flat in nature, returns kidney, bladder, large intestine meridian. It has the effects of solidifying essence and astringent intestines, reducing urination and stopping diarrhea. For slippery semen, enuresis, frequent urination, dysentery due to spleen deficiency, dyspnea and cough due to lung deficiency, spontaneous sweating and night sweating, metrorrhagia and vaginal discharge. In the prescription, Fructus Rosa Rosa Fructus is used as an envoy to harmonize the properties of the above-mentioned drugs by using its mild property while exerting its effect of strengthening essence and astringing intestines.
上述药物组合物以缓解疲劳为目标,并以补气为主,兼顾先天之气与后天之气,以及肾、脾、肝、肺等主要脏器,具有配伍合理,组方科学的特点,还具有益肾补肺,健脾益气之功效。The above-mentioned pharmaceutical composition aims at alleviating fatigue, mainly to invigorate qi, taking into account congenital qi and acquired qi, as well as major organs such as kidney, spleen, liver and lung, and has the characteristics of reasonable compatibility and scientific composition. It has the effects of nourishing the kidney and nourishing the lung, invigorating the spleen and replenishing qi.
在其中一个实施例中,所述组合物的有效成分由以下重量份的原料制备而成:刺五加13-17份,蛹虫草10-14份,山药6-10份,金樱子2-5份,女贞子4-7份。In one of the embodiments, the active ingredients of the composition are prepared from the following raw materials in parts by weight: 13-17 parts of Acanthopanax, 10-14 parts of Cordyceps militaris, 6-10 parts of Chinese yam, 2- 5 parts, 4-7 parts of Ligustrum lucidum.
本发明还公开了一种上述的抗疲劳组合物的制备方法,包括以下步骤:按重量份称取刺五加、蛹虫草、山药、金樱子和女贞子,干燥后粉碎,混合,即得。The invention also discloses a preparation method of the above-mentioned anti-fatigue composition, which includes the following steps: weighing Acanthopanax, Cordyceps militaris, Chinese yam, Fructus Rosa and Ligustrum lucidum by weight, crushing after drying, and mixing, namely have to.
本发明还公开了一种上述的抗疲劳组合物的制备方法,包括以下步骤:按重量份称取刺五加和女贞子,按照1g原料加入10~20ml体积百分浓度为35-65%的乙醇,60-80℃下提取1-3次,每次1~2h,烘干得干浸膏一;另按重量份称取蛹虫草、山药和金樱子,按照1g原料加入10~20ml的水,70-90℃下提取1-3次,每次1~2h,烘干得干浸膏二;将上述干浸膏一和干浸膏二混合均匀,即得。The invention also discloses a preparation method of the above-mentioned anti-fatigue composition, which includes the following steps: weighing Acanthopanax and Ligustrum lucidum by weight, adding 10-20ml of raw materials according to 1g, and the volume percentage is 35-65% Extract with ethanol at 60-80°C for 1-3 times, each time for 1-2 hours, and dry to obtain a dry extract; in addition, weigh Cordyceps militaris, Chinese yam and Rosa laevigata in parts by weight, and add 10-20ml according to 1g of raw materials extracted water at 70-90°C for 1-3 times, each time for 1-2 hours, and dried to obtain dry extract 2; mix the above-mentioned dry extract 1 and dry extract 2 evenly to obtain.
本发明还公开了一种抗疲劳的制剂,包括作为活性成分的上述的抗疲劳组合物,以及药学上可接受的载体。该抗疲劳组合物可以按照药学领域的常规生产方法制备,例如使活性成分与一种或多种载体混合,然后将其制成所需的剂型。The invention also discloses an anti-fatigue preparation, which comprises the above-mentioned anti-fatigue composition as an active ingredient and a pharmaceutically acceptable carrier. The anti-fatigue composition can be prepared according to conventional production methods in the field of pharmacy, such as mixing the active ingredient with one or more carriers, and then making it into a desired dosage form.
在其中一个实施例中,所述抗疲劳的制剂的剂型为口崩片,包括以下成分:In one of the embodiments, the dosage form of the anti-fatigue preparation is an orally disintegrating tablet, which includes the following ingredients:
将抗疲劳组合物制成能在口腔中迅速崩解的口崩片,部分有效成分可经舌下黏膜吸收,达到迅速起效的目的;其余部分在到达胃肠道之前即可分散成细微的颗粒,因此在胃肠道大面积分布,吸收点增多,生物利用度高。The anti-fatigue composition is made into an orally disintegrating tablet that can quickly disintegrate in the oral cavity. Part of the active ingredients can be absorbed through the sublingual mucosa to achieve the purpose of rapid onset of action; the rest can be dispersed into fine particles before reaching the gastrointestinal tract. Particles, so it is distributed in a large area of the gastrointestinal tract, with more absorption points and high bioavailability.
在其中一个实施例中,所述填充剂为微晶纤维素、乳糖淀粉、乳糖、预交化淀粉和甘露醇中的至少一种;所述崩解剂为低取代基羟基丙甲基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基淀粉钠和交联羧甲基纤维素钠中的至少一种;所述泡腾剂为碳酸氢钠与酒石酸、碳酸氢钠与枸橼酸、碳酸氢钠与富马酸、碳酸氢钠与维生素C中的至少一组;所述矫味剂为薄荷脑、薄荷素油、柠檬香精、甜蜜素和阿斯巴甜中的至少一种;所述润滑剂为硬脂酸镁、十二烷基硫酸镁和滑石粉中的至少一种;所述助流剂为微粉硅胶、滑石粉中的至少一种。In one of the embodiments, the filler is at least one of microcrystalline cellulose, lactose starch, lactose, precrossified starch and mannitol; the disintegrant is low-substituted hydroxypropylmethylcellulose , cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl starch and cross-linked sodium carboxymethylcellulose; the effervescent agent is sodium bicarbonate and tartaric acid, sodium bicarbonate and citric acid, carbonic acid At least one group of sodium bicarbonate and fumaric acid, sodium bicarbonate and vitamin C; the flavoring agent is at least one of menthol, peppermint oil, lemon flavor, cyclamate and aspartame; the lubricant The agent is at least one of magnesium stearate, magnesium lauryl sulfate and talcum powder; the glidant is at least one of micronized silica gel and talcum powder.
制备口崩片的关键在于选择合适的辅料,以确保压片时颗粒的流动性好、可压性强,压制后的片剂崩解速度快,此外还要保证所制得的片剂口感好。The key to preparing orally disintegrating tablets is to select appropriate excipients to ensure good fluidity and strong compressibility of the granules during tablet compression, and the disintegration speed of the compressed tablets is fast. In addition, it is also necessary to ensure that the prepared tablets have a good taste .
本发明以溶解性能、片剂硬度、润湿时间、吸水量等为指标筛选后,优选微晶纤维素、乳糖淀粉、乳糖、预交化淀粉和甘露醇中的至少一种作为填充剂。In the present invention, after screening based on solubility, tablet hardness, wetting time, water absorption, etc., at least one of microcrystalline cellulose, lactose starch, lactose, precrossified starch and mannitol is preferably used as a filler.
本发明以吸水膨胀性能和吸水速率为指标筛选后,优选低取代基羟基丙甲基纤维素(L-HPC)、交联聚乙烯吡咯烷酮(PVPP)、交联羧甲基淀粉钠(CCMS-Na)和交联羧甲基纤维素钠(CMC-Na)中的至少一种作为崩解剂。After the present invention takes water-absorbing swelling performance and water-absorbing rate as index screening, preferably low substituting group hydroxypropyl methylcellulose (L-HPC), cross-linked polyvinylpyrrolidone (PVPP), cross-linked carboxymethyl starch sodium (CCMS-Na ) and at least one of croscarmellose sodium (CMC-Na) as a disintegrant.
本发明通过对志愿者口感试验,掩蔽其微量苦涩味道后,优选薄荷脑、薄荷素油、柠檬香精、甜蜜素和阿斯巴甜中的至少一种作为矫味剂。According to the taste test of volunteers, at least one of menthol, peppermint oil, lemon essence, cyclamate and aspartame is preferably used as a flavoring agent after masking its slight bitter taste.
本发明还公开了一种上述的口崩片的制备方法,包括以下步骤:按重量份称取抗疲劳组合物,填充剂,崩解剂,泡腾剂,矫味剂,润滑剂和助流剂,分别过60-80目筛,于40℃-60℃烘干,随后将抗疲劳组合物分别与填充剂,崩解剂,泡腾剂和矫味剂以等量递加法混合均匀,再加入润滑剂和助流剂,混合均匀,粉末直接压片,即得。The invention also discloses a preparation method of the above-mentioned orally disintegrating tablet, comprising the following steps: weighing the anti-fatigue composition, filler, disintegrating agent, effervescent agent, corrective agent, lubricant and flow aid agent, passed through a 60-80 mesh sieve, and dried at 40°C-60°C, and then the anti-fatigue composition was mixed with filler, disintegrant, effervescent agent and flavoring agent in equal increments, and then Add lubricant and glidant, mix evenly, and directly compress the powder into tablets to obtain the product.
本发明还公开了一种上述的口崩片的制备方法,包括以下步骤:按重量份称取抗疲劳组合物,填充剂,崩解剂,泡腾剂,矫味剂,润滑剂和助流剂,分别过60-80目筛,于40℃-60℃烘干,随后将抗疲劳组合物分别与填充剂,崩解剂,泡腾剂和矫味剂以等量递加法混合均匀,再加入聚乙烯吡咯烷酮(PVP)的乙醇溶液,湿法制粒,将得到的湿颗粒在30℃~50℃烘干,整粒,加入润滑剂和助流剂,混合均匀,压制,即得。The invention also discloses a preparation method of the above-mentioned orally disintegrating tablet, comprising the following steps: weighing the anti-fatigue composition, filler, disintegrating agent, effervescent agent, corrective agent, lubricant and flow aid agent, passed through a 60-80 mesh sieve, and dried at 40°C-60°C, and then the anti-fatigue composition was mixed with filler, disintegrant, effervescent agent and flavoring agent in equal increments, and then Adding polyvinylpyrrolidone (PVP) ethanol solution, wet granulation, drying the obtained wet granules at 30°C to 50°C, sizing, adding lubricant and glidant, mixing evenly, and pressing to obtain the product.
与现有技术相比,本发明具有以下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
本发明的抗疲劳组合物,将刺五加,蛹虫草,山药,金樱子,女贞子相配合,以蛹虫草益肾补肺,补精髓,主补先天之气,为君药;以刺五加益气健脾,补肾安神,主补后天之气,为臣药;以山药益气养阴,女贞子补益肝肾,共为佐药;以金樱子固精涩肠,调和药性为使药。这几种原料相互配合,协同作用,共同起效,起到抗疲劳的功效。In the anti-fatigue composition of the present invention, Acanthopanax militaris, Cordyceps militaris, Chinese yam, Fructus Rosa, and Ligustrum lucidum are combined, and Cordyceps militaris is used to nourish the kidneys, nourish the lungs, nourish the essence, and mainly nourish the innate qi, which is the monarch drug; Acanthopanax acanthopanax nourishes Qi and invigorates the spleen, invigorates the kidney and calms the nerves, and mainly nourishes the acquired Qi, which is used as a ministerial drug; Chinese yam is used to nourish Qi and nourish yin, Ligustrum lucidum nourishes the liver and kidney, and is used as an adjuvant drug; Rosa japonica is used to strengthen essence and astringent intestines, harmonize The medicinal property is to make medicine. These several kinds of raw materials cooperate with each other, act synergistically, work together, and play the effect of anti-fatigue.
并且,将各原料以特定的比例配合后,具有非常好的抗疲劳效果,能够将小鼠的游泳时间延长至3.4倍,血清尿素氮含量降低18.3%,肝糖原含量提高2.3倍,并且能够将小鼠运动后乳酸升高倍数降低20.5%,具有非常好的效果。Moreover, after mixing the various raw materials in a specific ratio, it has a very good anti-fatigue effect, can extend the swimming time of mice to 3.4 times, reduce the content of serum urea nitrogen by 18.3%, increase the content of liver glycogen by 2.3 times, and can It has a very good effect by reducing the increase in lactic acid in mice after exercise by 20.5%.
本发明的抗疲劳口崩片,在服用时不需要额外的水送服,在口腔内仅依靠唾液即可在1分钟内迅速崩解,25分钟内口崩片中有效成分的溶出度大于75%。对口腔黏膜没有刺激性,口感好,无沙粒感,特别适于高强度脑力劳动者服用。The anti-fatigue orally disintegrating tablet of the present invention does not require additional water to be taken, and can be rapidly disintegrated within 1 minute in the oral cavity only relying on saliva, and the dissolution rate of the active ingredients in the orally disintegrating tablet is greater than 75% within 25 minutes. %. It is not irritating to the oral mucosa, has a good taste and no gritty feeling, and is especially suitable for high-intensity mental workers.
本发明的口崩片配方合理、制备工艺成熟,适于工业化规模生产。The orally disintegrating tablet of the invention has a reasonable formula and a mature preparation process, and is suitable for industrial scale production.
具体实施方式detailed description
以下结合具体实施例来详细说明本发明,但并不对本发明造成任何限制。The present invention is described in detail below in conjunction with specific examples, but does not impose any limitation on the present invention.
实施例1Example 1
一种抗疲劳组合物,所述组合物的有效成分由以下重量份的原料制备而成:An anti-fatigue composition, the active ingredient of which is prepared from the following raw materials in parts by weight:
刺五加15g,蛹虫草12g,山药8g,金樱子3g,女贞子5g。Acanthopanax 15g, Cordyceps militaris 12g, yam 8g, golden cherry 3g, privet privet 5g.
上述抗疲劳组合物具体制备方法如下:The specific preparation method of the above-mentioned anti-fatigue composition is as follows:
按处方量称取刺五加和女贞子,按照1g原料加入10ml溶剂的量加入体积百分浓度为50%的乙醇(即200ml),70℃下提取3次,每次2h,烘干得干浸膏一;另按处方量称取蛹虫草、山药和金樱子,按照1g原料加入10ml溶剂的量加入水(即230ml),80℃下提取3次,每次1h,烘干得干浸膏;将上述2种干浸膏混合均匀即得抗疲劳组合物A。Weigh Acanthopanax and Ligustrum lucidum according to the prescription amount, add 50% ethanol (i.e. 200ml) according to the amount of 10ml solvent added to 1g of raw materials, extract 3 times at 70°C, each time for 2h, and dry to obtain Dry extract 1; In addition, weigh Cordyceps militaris, Chinese yam and Rosa chinensis according to the prescription amount, add water (ie 230ml) according to the amount of 1g of raw materials and 10ml of solvent, extract 3 times at 80°C, 1h each time, and dry until dry Extract: Mix the above two dry extracts evenly to obtain the anti-fatigue composition A.
实施例2Example 2
一种抗疲劳组合物,所述组合物的有效成分由以下重量份的原料制备而成:An anti-fatigue composition, the active ingredient of which is prepared from the following raw materials in parts by weight:
刺五加10g,蛹虫草18g,山药5g,金樱子10g,女贞子3g。Acanthopanax 10g, Cordyceps militaris 18g, yam 5g, golden cherry 10g, Ligustrum lucidum 3g.
上述抗疲劳组合物具体制备方法如下:The specific preparation method of the above-mentioned anti-fatigue composition is as follows:
按处方量称取刺五加、蛹虫草、山药、金樱子和女贞子,干燥后粉碎,混合,即得抗疲劳组合物B。Acanthopanax, Cordyceps militaris, Chinese yam, Fructus Rosa and Ligustrum lucidum were weighed according to the prescription amount, dried, pulverized and mixed to obtain the anti-fatigue composition B.
实施例3Example 3
一种抗疲劳组合物,所述组合物的有效成分由以下重量份的原料制备而成:An anti-fatigue composition, the active ingredient of which is prepared from the following raw materials in parts by weight:
刺五加20g,蛹虫草8g,山药23g,金樱子3g,女贞子10g。Acanthopanax 20g, Cordyceps militaris 8g, yam 23g, golden cherry 3g, privet privet 10g.
上述抗疲劳组合物具体制备方法参照实施例1中的制备方法,制备得到抗疲劳组合物C。The specific preparation method of the above anti-fatigue composition refers to the preparation method in Example 1, and the anti-fatigue composition C is prepared.
实施例4Example 4
一种抗疲劳口崩片,处方如下:An anti-fatigue orally disintegrating tablet, the prescription is as follows:
本实施例的口崩片制备方法如下:The preparation method of the orally disintegrating tablet of the present embodiment is as follows:
精密称取处方量的抗疲劳组合物A,微晶纤维素、乳糖淀粉、碳酸氢钠、酒石酸、交联聚乙烯吡咯烷酮、低取代基羟基丙甲基纤维素、微粉硅胶、柠檬香精、甜蜜素及硬脂酸镁,过80目筛,于45℃烘干,采用等量递加法混合均匀。Precisely weigh the prescription amount of anti-fatigue composition A, microcrystalline cellulose, lactose starch, sodium bicarbonate, tartaric acid, cross-linked polyvinylpyrrolidone, low-substituent hydroxypropylmethylcellulose, micronized silica gel, lemon essence, cyclamate and magnesium stearate, passed through a 80-mesh sieve, dried at 45°C, and mixed uniformly by equal volume addition method.
取上述粉末直接压片,制得口崩片X,平均片重约250mg。The above powder was directly compressed into tablets to obtain orally disintegrating tablet X, with an average tablet weight of about 250 mg.
实施例5Example 5
一种抗疲劳口崩片,处方如下:An anti-fatigue orally disintegrating tablet, the prescription is as follows:
本实施例的口崩片制备方法如下:The preparation method of the orally disintegrating tablet of the present embodiment is as follows:
精密称取处方量的抗疲劳组合物B,甘露醇、乳糖淀粉、碳酸氢钠、维生素C、交联聚乙烯吡咯烷酮、微粉硅胶、柠檬香精、阿斯巴甜及硬脂酸镁,过60目筛,于60℃烘干,采用等量递加法混合均匀。Precisely weigh the prescribed amount of anti-fatigue composition B, mannitol, lactose starch, sodium bicarbonate, vitamin C, cross-linked polyvinylpyrrolidone, micropowder silica gel, lemon essence, aspartame and magnesium stearate, pass through 60 mesh Sieve, dry at 60°C, and mix evenly by equal volume addition method.
取上述粉末直接压片,制得口崩片Y,平均片重约400mg。The above powder was directly compressed into tablets to obtain orally disintegrating tablet Y with an average tablet weight of about 400 mg.
实施例6Example 6
一种抗疲劳口崩片,处方如下:An anti-fatigue orally disintegrating tablet, the prescription is as follows:
本实施例的口崩片制备方法如下:The preparation method of the orally disintegrating tablet of the present embodiment is as follows:
精密称取处方量的抗疲劳组合物C,甘露醇,微晶纤维素、预胶化淀粉、碳酸氢钠、富马酸、交联聚乙烯吡咯烷酮、阿斯巴甜,于40℃烘干,过80目筛,采用等量递加法混合均匀。用2.0%的PVP乙醇液制粒,40℃烘干,整粒后喷入柠檬香精,加入硬脂酸镁,压片,制得口崩片Z,平均片重约500mg。Precisely weigh the prescription amount of anti-fatigue composition C, mannitol, microcrystalline cellulose, pregelatinized starch, sodium bicarbonate, fumaric acid, cross-linked polyvinylpyrrolidone, aspartame, and dry at 40°C. Pass through a 80-mesh sieve, and mix evenly using the equal-volume incremental method. Granulate with 2.0% PVP ethanol solution, dry at 40°C, spray lemon essence after granulation, add magnesium stearate, and compress into tablets to obtain orally disintegrating tablet Z, with an average tablet weight of about 500 mg.
对比例1Comparative example 1
本对比例制备一种组合物,与实施例1的抗疲劳组合物基本相同,不同之处在于,本对比例的组合物由以下重量份的原料制备而成:This comparative example prepares a composition, which is basically the same as the anti-fatigue composition of Example 1, except that the composition of this comparative example is prepared from the following raw materials in parts by weight:
刺五加15g,山药8g,金樱子3g,女贞子5g。Acanthopanax 15g, yam 8g, golden cherry 3g, privet privet 5g.
参照实施例1的方法制备得到组合物D。Composition D was prepared according to the method of Example 1.
对比例2Comparative example 2
本对比例制备一种组合物,与实施例1的抗疲劳组合物基本相同,不同之处在于,本对比例的组合物由以下重量份的原料制备而成:This comparative example prepares a composition, which is basically the same as the anti-fatigue composition of Example 1, except that the composition of this comparative example is prepared from the following raw materials in parts by weight:
蛹虫草12g,山药8g,金樱子3g,女贞子5g。Cordyceps militaris 12g, yam 8g, golden cherry 3g, privet privet 5g.
参照实施例1的方法制备得到组合物E。Composition E was prepared with reference to the method of Example 1.
对比例3Comparative example 3
本对比例制备一种组合物,与实施例1的抗疲劳组合物基本相同,不同之处在于,本对比例的组合物由以下重量份的原料制备而成:This comparative example prepares a composition, which is basically the same as the anti-fatigue composition of Example 1, except that the composition of this comparative example is prepared from the following raw materials in parts by weight:
蛹虫草15g,刺五加12g。Cordyceps militaris 15g, Acanthopanax 12g.
参照实施例1的方法制备得到组合物F。Composition F was prepared according to the method of Example 1.
对比例4Comparative example 4
本对比例制备一种组合物,与实施例1的组合物基本相同,不同之处在于,本对比例的组合物由以下重量份的原料制备而成:This comparative example prepares a kind of composition, is substantially identical with the composition of embodiment 1, and difference is that, the composition of this comparative example is prepared by the raw material of following weight part:
刺五加15g,肉苁蓉12g,山药8g,金樱子3g,女贞子5g。Acanthopanax 15g, Cistanche 12g, yam 8g, Rosa chinensis 3g, Ligustrum lucidum 5g.
参照实施例1的方法制备得到组合物G。Composition G was prepared according to the method of Example 1.
对比例5Comparative example 5
本对比例制备一种组合物,与实施例1的组合物基本相同,不同之处在于,本对比例的组合物由以下重量份的原料制备而成:This comparative example prepares a kind of composition, is substantially identical with the composition of embodiment 1, and difference is that, the composition of this comparative example is prepared by the raw material of following weight part:
刺五加5g,蛹虫草5g,山药25g,金樱子15g,女贞子15g。Acanthopanax 5g, Cordyceps militaris 5g, yam 25g, golden cherry 15g, privet privet 15g.
参照实施例1的方法制备得到组合物H。Composition H was prepared according to the method of Example 1.
实验例1Experimental example 1
将上述制备得到的组合物A-H进行实验验证,考察其效果。Compositions A-H prepared above were subjected to experimental verification to investigate their effects.
1.实验药品:阳性药为生物健口服液(来源:太阳神集团有限公司,021D1)、实施例1-3制备的组合物A-C,对比例1-5制备的组合物D-G。1. Experimental drugs: the positive drugs are Biological Health Oral Liquid (source: Taiyangshen Group Co., Ltd., 021D1), compositions A-C prepared in Examples 1-3, and compositions D-G prepared in Comparative Examples 1-5.
2.实验动物:选用吉林大学实验动物中心提供的雄性BALB/C小鼠(2011-0004),清洁动物,体重18~22g,按体重随机分组。2. Experimental animals: Male BALB/C mice (2011-0004) provided by the Experimental Animal Center of Jilin University were selected, clean animals, weighing 18-22 g, and randomly divided into groups according to body weight.
3.实验分组:给药组以相当于人体推荐量的9倍剂量换算至小鼠等效剂量为给药剂量,即2.69mg/10g体重,阳性对照组给药剂量为0.03ml/10g,空白对照组正常饮食,连续等量喂食受试物30天,测定各项指标。3. Experimental grouping: The administration dose of the administration group was 9 times the dose equivalent to the human body’s recommended dose converted to the mouse equivalent dose, that is, 2.69mg/10g body weight, the administration dose of the positive control group was 0.03ml/10g, and the administration dose of the blank was 0.03ml/10g. The control group had a normal diet, fed the same amount of test substance continuously for 30 days, and measured various indexes.
4.实验仪器:游泳箱、铅丝、电子天平、酶标仪、紫外可见分光光度计、离心机、匀浆器。4. Experimental equipment: swimming box, lead wire, electronic balance, microplate reader, ultraviolet-visible spectrophotometer, centrifuge, homogenizer.
5.实验方法:5. Experimental method:
5.1游泳试验5.1 Swimming test
末次给予小鼠受试物30分钟后,小鼠尾根部负小鼠体重3%的铅丝,放入水温为30℃、水深35cm的游泳箱中。每一批小鼠下水之前均将水温调至30℃。每次最多放入6只小鼠,用秒表记录自游泳开始至力竭的时间,该时间为小鼠的游泳时间。30 minutes after the last administration of the mouse test substance, the base of the mouse's tail bears a lead wire of 3% of the mouse's body weight, and puts it into a swimming tank with a water temperature of 30°C and a water depth of 35cm. Before each batch of mice entered the water, the water temperature was adjusted to 30°C. A maximum of 6 mice were put in each time, and the time from the start of swimming to exhaustion was recorded with a stopwatch, which was the swimming time of the mice.
5.2血清尿素氮测定5.2 Determination of serum urea nitrogen
末次给予小鼠受试物30分钟后,将小鼠放于温度30℃的水中游泳90分钟,摘眼球取血,取血清测定其值。30 minutes after the last administration of the test substance to the mice, the mice were placed in water at a temperature of 30°C and swam for 90 minutes, the eyeballs were removed to obtain blood, and the serum was taken to determine its value.
5.3肝糖原测定5.3 Determination of liver glycogen
末次给予小鼠受试物30分钟后,立即处死。取肝脏经生理盐水漂洗后用滤纸吸干,精确称取肝脏200mg,加入4mL 5%的三氯醋酸(TCA),每管匀浆1分钟,将匀浆液倒入离心管,3000转/分离心15分钟,将上清液转移至另一试管内。在沉淀中再加4mL TCA,匀浆1分钟,再次离心15分钟,取上清液,并与第一次离心的上清液合并,充分混匀。取1mL上清液放入10mL离心管中,每管加入95%的乙醇4mL,充分混匀至两种液体间不留有界面。用干净塞子塞上,室温下竖直放置过夜。沉淀完全后,将试管于3000转/分离心15分钟。小心倒掉上清液并使试管倒立放置10分钟。用2mL蒸馏水溶解糖原,加水时将管壁的糖原洗下,使之完全溶解。Thirty minutes after the last administration of the test substance to the mice, they were sacrificed immediately. The liver was rinsed with normal saline and blotted dry with filter paper. Accurately weighed 200 mg of the liver, added 4 mL of 5% trichloroacetic acid (TCA), homogenized each tube for 1 minute, poured the homogenate into a centrifuge tube, and centrifuged at 3000 rpm. After 15 minutes, transfer the supernatant to another tube. Add 4 mL of TCA to the pellet, homogenize for 1 minute, centrifuge again for 15 minutes, take the supernatant, combine it with the supernatant of the first centrifugation, and mix thoroughly. Take 1 mL of the supernatant and put it into a 10 mL centrifuge tube, add 4 mL of 95% ethanol to each tube, and mix well until there is no interface between the two liquids. Plug with clean stoppers and store upright overnight at room temperature. After precipitation was complete, the tube was centrifuged at 3000 rpm for 15 minutes. Carefully discard the supernatant and invert the tube for 10 minutes. Dissolve the glycogen with 2mL distilled water, and wash the glycogen on the tube wall when adding water to dissolve it completely.
试管空白:吸2mL蒸馏水到干净离心管。Test tube blank: pipette 2 mL of distilled water into a clean centrifuge tube.
标准管:将0.5mL葡萄糖标准液(含100mg/dL葡萄糖)和1.5mL蒸馏水放入同样的离心管。Standard tube: Put 0.5mL glucose standard solution (containing 100mg/dL glucose) and 1.5mL distilled water into the same centrifuge tube.
测定:将10mL蒽酮试剂用力加入各管,液流直接进入管子中央,保证充分混合好。从管子中注入蒽酮试剂起,将管子放入冷水中,达到冷水温度后,将其浸入沸水浴15分钟,然后移到冷水浴,冷却到室温。将管内液体移入比色皿,620nm波长,用试剂空白调零后测定样品管和标准管的吸光度。根据肝脏重量换算成肝糖原含量(以mg/g肝表示)。Determination: Add 10mL of anthrone reagent to each tube forcefully, and the liquid flow directly into the center of the tube to ensure thorough mixing. From the time the anthrone reagent is injected into the tube, place the tube in cold water. After reaching the temperature of the cold water, immerse it in a boiling water bath for 15 minutes, then move to the cold water bath and cool to room temperature. Transfer the liquid in the tube to a cuvette, measure the absorbance of the sample tube and the standard tube after zeroing with a reagent blank at a wavelength of 620nm. Liver glycogen content (expressed in mg/g liver) was converted based on liver weight.
5.4血乳酸测定5.4 Determination of blood lactic acid
末次给予小鼠受试物30分钟后,放入水温30℃、水深35cm的游泳箱中游泳10分钟后取出,即刻采尾血20μL,加入盛有40μL溶血剂的试管中混匀,用生物传感分析仪测定血乳酸值。采用同样的方法测定游泳前和游泳后休息20分钟时的血乳酸水平。30 minutes after the last administration of the test substance to the mice, put them into a swimming tank with a water temperature of 30°C and a water depth of 35 cm for 10 minutes and then take them out. Immediately collect 20 μL of tail blood, add it to a test tube containing 40 μL of hemolytic agent and mix well, A sensory analyzer was used to measure the blood lactate value. The same method was used to measure the blood lactate level before swimming and after swimming for 20 minutes.
6.实验结果:将实验数据进行统计学分析。6. Experimental results: Statistical analysis was performed on the experimental data.
实验结果如下:The experimental results are as follows:
1)游泳实验:结果请见下表。1) Swimming test: See the table below for the results.
表1:小鼠负重游泳时间的实验结果()Table 1: Experimental results of weight-bearing swimming time of mice ( )
从上述结果中,我们可以看出,本发明实施例1-3的组合物A-C,小鼠的游泳时间均长于空白组,说明该组合物具有抗疲劳的效果。且组合物A能够将小鼠的游泳时间延长至3.4倍,具有非常好的效果。From the above results, we can see that in the compositions A-C of Examples 1-3 of the present invention, the swimming time of the mice was longer than that of the blank group, indicating that the compositions have an anti-fatigue effect. And the composition A can extend the swimming time of mice to 3.4 times, which has a very good effect.
对比例1-5的组合物D-H的小鼠游泳时间虽优于空白组,但不如A-C组,说明对比例1-5的组合物D-H也具有抗疲劳的作用,但其效果不如A-C组。Although the swimming time of the mice in the compositions D-H of Comparative Examples 1-5 was better than that of the blank group, it was not as good as that of the A-C groups, indicating that the compositions D-H of Comparative Examples 1-5 also had anti-fatigue effects, but the effect was not as good as that of the A-C groups.
阳性组的小鼠游泳时间虽优于组合物D-H组,与组合物C组相当,但不如组合物A、B组,说明其效果较好,但仍不如组合物A、B。Although the swimming time of the mice in the positive group was better than that of the composition D-H group, and comparable to that of the composition C group, it was not as good as that of the composition A and B groups, indicating that the effect was better, but still not as good as that of the composition A and B.
2)血清尿素氮测定:结果请见下表。2) Determination of serum urea nitrogen: see the table below for the results.
表2:小鼠血清尿素氮含量的实验结果()Table 2: Experimental results of serum urea nitrogen content in mice ( )
从上述结果中,我们可以看出,本发明实施例1-3的组合物A-C,小鼠的血清尿素氮含量均低于空白组,说明该组合物具有抗疲劳的效果。且组合物A能够将小鼠的血清尿素氮含量降低18.3%,具有非常好的效果。From the above results, we can see that the serum urea nitrogen content of the mice in the compositions A-C of Examples 1-3 of the present invention are all lower than those of the blank group, indicating that the compositions have an anti-fatigue effect. And composition A can reduce the serum urea nitrogen content of mice by 18.3%, which has a very good effect.
对比例1-5的组合物D-H的小鼠血清尿素氮含量虽低于空白组,但不如A-C组,说明对比例1-5的组合物D-H也具有抗疲劳的作用,但其效果不如A-C组。Although the serum urea nitrogen content of the mice in the compositions D-H of Comparative Examples 1-5 was lower than that of the blank group, it was not as good as that of the A-C groups, indicating that the compositions D-H of Comparative Examples 1-5 also had anti-fatigue effects, but the effect was not as good as that of the A-C groups .
阳性组的小鼠血清尿素氮含量虽低于组合物D-H组,与组合物C组相当,但仍比组合物A、B组高,说明其效果较好,但仍不如组合物A、B组。Although the serum urea nitrogen content of the mice in the positive group was lower than that of the composition D-H group and equivalent to that of the composition C group, it was still higher than that of the composition A and B groups, indicating that the effect was better, but still not as good as that of the composition A and B groups .
3)肝糖原测定:结果请见下表。3) Determination of liver glycogen: Please see the table below for the results.
表3:小鼠肝糖原含量的实验结果()Table 3: Experimental results of mouse liver glycogen content ( )
从上述结果中,我们可以看出,本发明实施例1-3的组合物A-C,小鼠的肝糖原含量均高于空白组,说明该组合物具有抗疲劳的效果。且组合物A能够将小鼠的肝糖原含量提高2.3倍,具有非常好的效果。From the above results, we can see that the liver glycogen content of mice in the compositions A-C of Examples 1-3 of the present invention is higher than that of the blank group, indicating that the composition has an anti-fatigue effect. And composition A can increase the liver glycogen content of mice by 2.3 times, which has a very good effect.
对比例1-5的组合物D-H的小鼠肝糖原含量虽高于空白组,但不如A-C组,说明对比例1-5的组合物D-H也具有抗疲劳的作用,但其效果不如A-C组。Although the mouse liver glycogen content of the composition D-H of comparative examples 1-5 is higher than that of the blank group, it is not as good as that of the A-C group, indicating that the composition D-H of the comparative examples 1-5 also has anti-fatigue effect, but its effect is not as good as that of the A-C group .
阳性组的小鼠肝糖原含量虽高于组合物D-H组,但仍比组合物A-C组低,说明其效果较好,但仍不如组合物A-C组。Although the mouse liver glycogen content of the positive group was higher than that of the composition D-H group, it was still lower than that of the composition A-C group, indicating that the effect was better, but still not as good as that of the composition A-C group.
4)血乳酸测定:结果请见下表。4) Determination of blood lactic acid: see the table below for the results.
表4:各组游泳10分钟对小鼠血乳酸值影响的实验结果()Table 4: Experimental results of 10 minutes of swimming in each group on the blood lactic acid value of mice ( )
从上述结果中,我们可以看出,本发明实施例1-3的组合物A-C,小鼠运动后乳酸升高倍数均小于空白组,说明该组合物具有抗疲劳的效果。且组合物B能够将小鼠的乳酸升高倍数降低20.5%,具有非常好的效果。From the above results, we can see that in the compositions A-C of Examples 1-3 of the present invention, the increase in lactic acid of mice after exercise is smaller than that of the blank group, indicating that the composition has an anti-fatigue effect. And the composition B can reduce the increase rate of lactic acid in mice by 20.5%, which has a very good effect.
对比例1-5的组合物D-H的乳酸升高倍数虽低于空白组,但不如A-C组,说明对比例1-5的组合物D-H也具有抗疲劳的作用,但其效果不如A-C组。Although the lactic acid increase multiple of the composition D-H of Comparative Examples 1-5 is lower than that of the blank group, it is not as good as that of the A-C group, indicating that the composition D-H of Comparative Examples 1-5 also has anti-fatigue effect, but its effect is not as good as that of the A-C group.
阳性组的小鼠乳酸升高倍数虽低于组合物D-H组,与组合物C组相当,但仍比组合物A、B组高,说明其效果较好,但仍不如组合物A、B组。Although the increase in lactic acid of mice in the positive group was lower than that of the composition D-H group and comparable to that of the composition C group, it was still higher than that of the composition A and B groups, indicating that the effect was better, but still not as good as that of the composition A and B groups .
4.结论4 Conclusion
经口服给予小鼠实施例1-3制备的组合物30天,能明显延长小鼠游泳时间、显著降低小鼠运动后血清尿素氮,显著提高小鼠运动后血乳酸清除的速度,并显著提高小鼠肝糖原含量。根据《保健食品功能学评价程序和检验方法》的规定,本发明的保健品具有抗疲劳作用。Oral administration of the composition prepared in Examples 1-3 to mice for 30 days can significantly prolong the swimming time of mice, significantly reduce the serum urea nitrogen of mice after exercise, significantly increase the speed of blood lactic acid clearance of mice after exercise, and significantly improve Mouse liver glycogen content. According to the provisions of "Health Food Functional Evaluation Procedure and Test Method", the health product of the present invention has anti-fatigue effect.
并且,由实验结果可以看出,本发明能缓解疲劳的产生并能加速疲劳的消除,改善机体的状况,可降低血清尿素氮和加速清除血乳酸,增加肝糖原含量,并且效果显著,是抗疲劳的理想产品。And, as can be seen from the experimental results, the present invention can alleviate the occurrence of fatigue and accelerate the elimination of fatigue, improve the condition of the body, reduce serum urea nitrogen and accelerate the removal of blood lactic acid, increase liver glycogen content, and the effect is remarkable, is Ideal product against fatigue.
实验例2Experimental example 2
将上述制备得到的口崩片X-Z进行实验验证,考察其效果。The orally disintegrating tablet X-Z prepared above was subjected to experimental verification to investigate its effect.
1、体外崩解时间测定1. Determination of disintegration time in vitro
取5mL试管为容器,加入2mL蒸馏水为介质,将试管置于温度为37℃的水浴锅中水浴,将实施例3-6制备的到的口崩片放入管中即开始计时,直到片剂完全崩解成颗粒的时间为崩解时间,整个过程静态测定。每组测定10片,具体结果如下表所示,并计算平均崩解时间。Take a 5mL test tube as a container, add 2mL of distilled water as a medium, place the test tube in a water bath at a temperature of 37°C, put the orally disintegrating tablet prepared in Example 3-6 into the tube and start timing until the tablet The time for complete disintegration into granules is the disintegration time, and the whole process is measured statically. Each group measured 10 tablets, the specific results are shown in the table below, and the average disintegration time was calculated.
表5:体外崩解时间Table 5: In vitro disintegration time
从上述结果中,我们可以看出,体外崩解时间为50.74±5.50s,49.10±5.92s,46.63±4.39s,均在1分钟内迅速崩解,具有崩解效果好的特点。From the above results, we can see that the in vitro disintegration time is 50.74±5.50s, 49.10±5.92s, 46.63±4.39s, all disintegrate rapidly within 1 minute, and have the characteristics of good disintegration effect.
2、口腔内崩解时间测定2. Determination of oral disintegration time
选用6名健康志愿者,取实施例4-6制得的口腔崩解片X-Z,放入志愿者口中,即开始记录口崩片在口腔中完全崩解的时间。每组测定10片,具体结果如下表所示,并计算平均口腔崩解时间。Select 6 healthy volunteers, take the orally disintegrating tablets X-Z prepared in Examples 4-6, put them into the mouths of the volunteers, and start recording the time for the orally disintegrating tablets to completely disintegrate in the oral cavity. 10 tablets were measured for each group, and the specific results are shown in the table below, and the average oral disintegration time was calculated.
计算平均崩解时间。结果如表6,口内崩解时间为50.22±3.11s。Calculate the average disintegration time. The results are shown in Table 6, and the oral disintegration time was 50.22±3.11s.
表6:口腔崩解时间Table 6: Oral Disintegration Time
从上述结果中,我们可以看出,崩解时间为51.46±4.32s,50.20±5.18s,47.16±4.06s,均在1分钟内迅速崩解,具有崩解效果好的特点。并且,志愿者反映该口崩片对口腔黏膜没有刺激性,口感好,无沙粒感。From the above results, we can see that the disintegration time is 51.46±4.32s, 50.20±5.18s, 47.16±4.06s, all disintegrate rapidly within 1 minute, and have the characteristics of good disintegration effect. Moreover, the volunteers reported that the orally disintegrating tablet has no irritation to the oral mucosa, has a good taste, and has no gritty feeling.
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。The above-mentioned embodiments only express several implementation modes of the present invention, and the descriptions thereof are relatively specific and detailed, but should not be construed as limiting the patent scope of the present invention. It should be pointed out that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent for the present invention should be based on the appended claims.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410789238.7A CN104491310B (en) | 2014-12-17 | 2014-12-17 | Anti-fatigue composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410789238.7A CN104491310B (en) | 2014-12-17 | 2014-12-17 | Anti-fatigue composition and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104491310A CN104491310A (en) | 2015-04-08 |
| CN104491310B true CN104491310B (en) | 2017-08-04 |
Family
ID=52932824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410789238.7A Active CN104491310B (en) | 2014-12-17 | 2014-12-17 | Anti-fatigue composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491310B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825530A (en) * | 2015-04-25 | 2015-08-12 | 哈药集团中药二厂 | Preparation method of oroxylum indicum throat-clearing buccal tablet |
| CN104738641B (en) * | 2015-04-25 | 2017-05-31 | 哈药集团中药二厂 | A kind of preparation method of the antifatigue lozenge of Roselle |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211222A (en) * | 2013-05-03 | 2013-07-24 | 江南大学 | Composition with effect of relieving physical fatigue |
| CN103271356A (en) * | 2013-06-14 | 2013-09-04 | 海南通宝投资有限公司 | Composition for enhancing immunity and relieving physical fatigue and preparation method of composition |
-
2014
- 2014-12-17 CN CN201410789238.7A patent/CN104491310B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211222A (en) * | 2013-05-03 | 2013-07-24 | 江南大学 | Composition with effect of relieving physical fatigue |
| CN103271356A (en) * | 2013-06-14 | 2013-09-04 | 海南通宝投资有限公司 | Composition for enhancing immunity and relieving physical fatigue and preparation method of composition |
Non-Patent Citations (3)
| Title |
|---|
| "刺五加提取物抗疲劳作用的研究";徐峰 等;《食品科学》;20051231;453-456 * |
| "抗疲劳防治亚健康中药整理与研究";周宝宽;《中华中医药学刊》;20081231;193-195 * |
| "蛹虫草多糖对小鼠抗疲劳作用的研究";江海涛 等;《食用菌学报》;20140331;55-59 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104491310A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103271346B (en) | Health-care food for relieving physical fatigue | |
| US10701963B2 (en) | Nutritional composition for moisturizing lung and method for preparing the same | |
| CN102988703A (en) | Traditional Chinese medicine preparation for treating kidney-yang deficiency and preparation method thereof | |
| CN107126485A (en) | It is a kind of to aid in improving Chinese medicine composition of sleep and its preparation method and application | |
| CN111588804A (en) | Medicinal and edible formula for tonifying primordial qi | |
| CN103948029B (en) | A kind of yin-deficiency constitution protective foods and its preparation method | |
| CN104491310B (en) | Anti-fatigue composition and its preparation method and application | |
| CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
| CN106237268B (en) | It is a kind of to treat schizoid pharmaceutical composition and its application | |
| CN101129699A (en) | Prepared rehmannia root-angelica sinensis-yin pill | |
| CN102266427B (en) | Cartialgenous and angelica wine for maintaining beauty and keeping young as well as preparation method and application thereof | |
| CN118044611A (en) | Lung-clearing and lung-protecting nutrition product | |
| CN115414441A (en) | Traditional Chinese medicine composition with effects of nourishing blood, regulating menstruation, removing blood stasis and removing ecchymoses as well as preparation method and application thereof | |
| CN102579686A (en) | Traditional Chinese medicine lozenge and preparing method thereof | |
| CN114224956A (en) | Anti-fatigue composition containing acanthopanax senticosus and preparation and application thereof | |
| CN105998140A (en) | Herba rhodiola buccal tablets | |
| CN112755155A (en) | Composition for protecting liver and kidney, regulating immunity and improving physique and preparation method thereof | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN104887739A (en) | Angelica sinensis-astragalus membranaceus blood replenishing oral tablets, as well as preparation method and application thereof | |
| CN112023010A (en) | Traditional Chinese medicine composition for slimming, preparation method thereof, oral medicine and application | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN108721480A (en) | A kind of compound Chinese medicinal preparation for treating a variety of insomnias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| OL01 | Intention to license declared | ||
| OL01 | Intention to license declared |